Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference19 articles.
1. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013
2. Atezolizumab in advanced non-small lung cancer;Ilie;J Thorac Dis,2017
3. The B7-H1 (PD-L1) T lymphocyte inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors;Ghebeh;Neoplasia,2006
4. Programmed cell death1ligand1and tumor infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer;Hamanishi;Proc Natl Acad Sci U S A,2007
5. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance;Wu;Acta Histochem,2006
Cited by 89 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 2.高齢者における薬疹および薬剤誘発性皮膚疾患;Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics;2023-10-25
2. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration;Journal of Oncology Pharmacy Practice;2023-10-11
3. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment;JAMA Dermatology;2023-10-01
4. Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction;JAAD Case Reports;2023-10
5. Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study;Cancer Medicine;2023-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3